Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary objective of this study is to compare the rates of achieving undetectable measurable residual disease (MRD) in the bone marrow with elranatamab and daratumumab employed as post-induction consolidation and maintenance treatment (Arm A) versus autologous stem cell transplant (ASCT) followed by lenalidomide and daratumumab treatment (Arm B).

NCT Number	NCT06974786
Lead Sponsor	SCRI Development Innovations, LLC Collaborators: Pfizer, coMMit, Myeloma Trials, Innovated
Conditions	Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Enrollment	100 participants
Start Date	2025-08-08
Primary Completion	2032-11 (estimated)
Study Completion	2033-04 (estimated)
Updated on ClinicalTrials.gov	2026-06-04